March 30, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
See all press releases >>
